DE60025905D1 - In vitro methode zur synchronisation von oozytenreifung - Google Patents

In vitro methode zur synchronisation von oozytenreifung

Info

Publication number
DE60025905D1
DE60025905D1 DE60025905T DE60025905T DE60025905D1 DE 60025905 D1 DE60025905 D1 DE 60025905D1 DE 60025905 T DE60025905 T DE 60025905T DE 60025905 T DE60025905 T DE 60025905T DE 60025905 D1 DE60025905 D1 DE 60025905D1
Authority
DE
Germany
Prior art keywords
synchronization
vitro method
oxygen treatment
oxygen
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60025905T
Other languages
English (en)
Other versions
DE60025905T2 (de
Inventor
Christian Grondahl
Host Hansen
Alexander Ruebig
Christa Hegele-Hartung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of DE60025905D1 publication Critical patent/DE60025905D1/de
Application granted granted Critical
Publication of DE60025905T2 publication Critical patent/DE60025905T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0608—Germ cells
    • C12N5/0609—Oocytes, oogonia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C12N2501/392—Sexual steroids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/10—Conditioning of cells for in vitro fecondation or nuclear transfer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60025905T 1999-02-24 2000-02-23 In vitro methode zur synchronisation von oozytenreifung Expired - Fee Related DE60025905T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DKPA199900255 1999-02-24
DK25599 1999-02-24
US13081699P 1999-04-23 1999-04-23
US130816P 1999-04-23
DK131099 1999-09-16
DKPA199901310 1999-09-16
PCT/DK2000/000074 WO2000050066A1 (en) 1999-02-24 2000-02-23 Treatment of infertility

Publications (2)

Publication Number Publication Date
DE60025905D1 true DE60025905D1 (de) 2006-04-20
DE60025905T2 DE60025905T2 (de) 2006-09-14

Family

ID=27220546

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60025905T Expired - Fee Related DE60025905T2 (de) 1999-02-24 2000-02-23 In vitro methode zur synchronisation von oozytenreifung

Country Status (13)

Country Link
US (1) US6585982B1 (de)
EP (1) EP1156822B1 (de)
JP (1) JP2002537349A (de)
KR (1) KR20010093280A (de)
CN (1) CN1353617A (de)
AT (1) ATE317266T1 (de)
AU (1) AU2794100A (de)
BR (1) BR0008468A (de)
CZ (1) CZ20012967A3 (de)
DE (1) DE60025905T2 (de)
ES (1) ES2258445T3 (de)
HU (1) HUP0200157A3 (de)
WO (1) WO2000050066A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
EP1157096A2 (de) * 1999-02-26 2001-11-28 Novo Nordisk A/S Kulturmedium mit meiosis-aktivierende sterolen (mas) und verfahren zur in vitro fertilisation
US20030153808A1 (en) * 2000-02-25 2003-08-14 Christa Hegele-Hartung Implantation rate using ff-mas
AU3376501A (en) * 2000-02-25 2001-09-03 Novo Nordisk A/S Improvement of implantation rate
WO2001088098A2 (en) * 2000-05-18 2001-11-22 Schering Aktiengesellschaft Fertilization of aged oocytes
EP1287033A2 (de) * 2000-05-25 2003-03-05 Queen's University At Kingston Sperma protein pt32, c-yes aus spermien und cytoplasma von oozyten, sowie verwendung dieser proteine
EP1216701A1 (de) * 2000-12-22 2002-06-26 Schering Aktiengesellschaft Verfahren zur Erhöhung der Konzentration von Meiosis-aktivierenden Sterolen in der Cholesterolsynthese und die Verwendung von potenten Hemmstoffen in das Verfahren
EP1245572A1 (de) 2001-03-26 2002-10-02 Schering Aktiengesellschaft Aminosterol-Verbindungen, ihre Verwendung zur Herstellung Meiose-regulierender Medikamenten und ein Vefahren zu ihrer Herstellung
AR036592A1 (es) * 2001-09-12 2004-09-22 Applied Research Systems Uso de gch en la hiperestimulacion ovarica controlada
AU2002324183B2 (en) * 2001-09-12 2007-10-25 Merck Serono Sa Use of hCG and LH in controlled ovarian hyperstimulation
EA009279B1 (ru) * 2001-09-12 2007-12-28 Апплайд Резеч Системз Арс Холдинг Н.В. Применение лютеинизирующего гормона человека, в том числе в сочетании с фолликулостимулирующим гормоном, для содействия имплантации и/или снижения частоты выкидышей
WO2003070766A2 (en) * 2002-02-22 2003-08-28 Novo Nordisk A/S A transducer of mas signalling
JP2005518823A (ja) 2002-03-08 2005-06-30 マクギル・ユニバーシテイ 未成熟ヒト卵母細胞の体外成熟
KR20050058285A (ko) * 2002-06-07 2005-06-16 아레스 트레이딩 에스.에이. 조절된 난소 과자극 방법 및 이런 방법에 이용되는제약학적 키트
ES2547953T3 (es) 2004-05-17 2015-10-09 The General Hospital Corporation Composiciones que comprenden células madre germinales femeninas y métodos de uso de las mismas
MY154677A (en) 2006-03-07 2015-07-15 Shroff Geeta Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
AU2012242591B2 (en) 2011-04-14 2014-10-23 The General Hospital Corporation Compositions and methods for autologous germline mitochondrial energy transfer
CA2847292A1 (en) 2011-06-29 2013-01-03 The General Hospital Corporation Compositions and methods for enhancing bioenergetic status in female germ cells
US20150272622A1 (en) 2011-12-22 2015-10-01 Previvo Genetics, Llc Recovery and processing of human embryos formed in vivo

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5563059A (en) * 1993-02-23 1996-10-08 Genentech, Inc. Use of human inhibin and human activin to increase the number of mature primate oocytes
US5716777A (en) * 1994-06-23 1998-02-10 Novo Nordisk A/S Regulation of meiosis using sterols
HUP9800731A3 (en) * 1995-03-06 2000-03-28 Novo Nordisk As Stimulation of meiosis
AU6122696A (en) * 1995-06-23 1997-01-22 Novo Nordisk A/S Meiosis regulating compounds
KR19990028366A (ko) * 1995-06-23 1999-04-15 켈베르그 라르스 감수분열 조절 화합물
CA2275683A1 (en) * 1996-12-20 1998-07-02 Frederik Christian Gronvald Meiosis regulating compounds
CN1259138A (zh) * 1997-06-04 2000-07-05 阿克佐诺贝尔公司 调节减数分裂的17β－烯丙氧基(硫代)烷基－雄甾烷衍生物
US5866599A (en) * 1997-06-06 1999-02-02 Basf Aktiengesellschaft Fungicidal mixtures
ATE361091T1 (de) * 1999-02-24 2007-05-15 Novo Nordisk As Behandlung von unfruchtbarkeit

Also Published As

Publication number Publication date
WO2000050066A1 (en) 2000-08-31
EP1156822B1 (de) 2006-02-08
US6585982B1 (en) 2003-07-01
BR0008468A (pt) 2002-02-05
HUP0200157A3 (en) 2002-06-28
JP2002537349A (ja) 2002-11-05
AU2794100A (en) 2000-09-14
KR20010093280A (ko) 2001-10-27
CN1353617A (zh) 2002-06-12
CZ20012967A3 (cs) 2001-12-12
EP1156822A1 (de) 2001-11-28
HUP0200157A2 (hu) 2002-05-29
ES2258445T3 (es) 2006-09-01
DE60025905T2 (de) 2006-09-14
ATE317266T1 (de) 2006-02-15

Similar Documents

Publication Publication Date Title
DE60025905D1 (de) In vitro methode zur synchronisation von oozytenreifung
ATE361977T1 (de) In vitro verfahren zur induzierung der regulierten pankreatische-hormon produktion in nicht-pankreatischen inselngeweben, damit verbundene pharmazeutische zusammenseztzungen
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
DE60114002D1 (de) VERFAHREN ZUR HERSTELLUNG KRISTALLINEr PARTIKEL ZUR INHALATION
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
SG148217A1 (en) Method for treating adamts-5-associated disease
MY138883A (en) Use of asiatic acid for treatment of cencer
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
BR0109975A (pt) Método para produzir ansamitocinas
DE50105968D1 (de) VERFAHREN ZUR HERSTELLUNG VON AlKYLVERBRÜCKTEN LIGANDSYSTEMEN UND ÜBERGANGSMETALLVERBINDUNGEN
NO984950L (no) Forbindelser med veksthormonfrigj°rende egenskaper
MY141020A (en) Novel pparalpha and ppargamma agonists
ATE294771T1 (de) Mikrobielles verfahren zur herstellung von pravastatin
GB9907571D0 (en) Compounds
UA83203C2 (uk) Тіазол-(бі)циклоалкілкарбоксаніліди, засіб на їх основі та застосування для боротьби з небажаними мікроорганізмами
DE50015890D1 (de) Verfahren zur synchronisation
ATE397959T1 (de) Verwendung von erbb-rezeptorliganden zur behandlung von diabetes
ATE252383T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE446952T1 (de) Herstellungsverfahren von 2-cyanopyridinen
IL148234A0 (en) Composition for ivf
MY127328A (en) 5-amino-1-pentene-3-ol substituted derivatives
NO20015285D0 (no) Fremstillingsprosess for n¶ringsmiddelfermenterende midler
ATE537160T1 (de) Verfahren zur herstellung von 14beta- hydroxybaccatin-iii-1,14-carbonat
DE60236303D1 (de) Verfahren zur herstellung von 14-beta-hydroxybaccatin-iii-1,14-carbonat
BR0015335A (pt) Substratos de policarbonato

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee